Chemotherapy Market Size

Global Chemotherapy Market Overview

Chemotherapy Market Size was valued at USD 8.2 Billion in 2022. The chemotherapy market industry is projected to grow from USD 8.81 Billion in 2023 to USD 15.72 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032).Factors such as rising cancer prevalence, an increase in the number of sufferers receiving chemotherapy and radiotherapy treatments, an increase in compliance with chemotherapy drugs due to various treatment options, and the availability of combination therapies are the key market drivers enhancing the market growth. The market for chemotherapy is anticipated to expand due to advances in drug delivery, development, and the shift toward biologics.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Chemotherapy Market Trends

• Growing cancer rates are fueling the market growth

Market CAGR for chemotherapy is driven by the rising number of cancer patients. Cancer incidence has climbed globally, overtaking cardiovascular diseases as the second greatest cause of death. This phenomenon is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. For instance, the World Health Organisation (WHO) estimates that there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018. Therefore, it is anticipated that the rising incidence of cancer will increase the demand for oncology cancer medications globally throughout the projection period. Furthermore, the industry will benefit from the population's growing cancer awareness in the next years.

Figure 1: Total estimated occurrence of different types of cancer in both type of genders in 2020

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cancer treatment is developing more quickly than ever. Emerging from the research and development pipeline are several novel treatments frequently combined with other brand-new or current medications. Numerous pharmaceutical companies are funding these revolutionary medication development projects to treat cancer. For instance, Pfizer purchased Array BioPharma in June 2019, intending to expand its oncology footprint and pipeline, starting with a melanoma combination medication that has been licensed and is currently testing for metastatic colorectal cancer. This is expected to accelerate market expansion and grow consumer desire for biosimilar and biologic products.

Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Rising chemo awareness and an increase in patients undergoing these treatments are further factors expected to speed up the market's growth rate. Because of aging demographics, the demand for chemotherapeutic medications will also expand. Thus, driving the chemotherapy market revenue.

Chemotherapy Market Segment Insights

Chemotherapy Drug Class Insights

The chemotherapy market segmentation, based on drug class, includes mitotic inhibitors, alkylating agents, antimetabolites, topoisomerase inhibitors and antitumor antibiotics. The alkylating agent segment dominated the market, accounting for 39.7% of market revenue (3.3 Billion). Alkylating substances result in DNA strand breakage, odd base pairing, or cross-linking of DNA strands, which prevents cell division. Generally speaking, alkylating chemicals are considered cell cycle phase nonspecific, meaning they can kill cells at different points in the cell cycle. The market for anti-metabolite drugs will expand dramatically as cancer rates increase globally. The anti-metabolite medication sector will also grow due to increased pipeline research and rising healthcare costs.

Figure 2: Chemotherapy Market by Drug Class, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Chemotherapy Indication Insights

The chemotherapy market segmentation, based on indication, includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia and ovarian cancer. In 2022, leukemia dominated the market. Leukaemias with a sluggish growth rate may require monitoring as part of their treatment. Radiation therapy, stem cell transplant, and chemotherapy are sometimes used together to treat severe leukemias. Furthermore, the cases of breast cancer are also rising at a significant rate. The sector's growth is driven by the increasing prevalence of breast cancer in women, the variety of therapies available, and improved methods for breast cancer diagnostics using cutting-edge technologies.

Chemotherapy Route of Drug Administration Insights

The chemotherapy market segmentation, based on the route of drug administration, includes intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal and intraventricular/intrathecal. The market's largest contributor, the oral category, is anticipated to expand at a major rate over the projected period. An oral cancer treatment drug is available as a pill, capsule, or liquid. However, the intravenous route witnessed the fastest growth rate. Since they are administered intravenously, chemotherapy drugs function more quickly than oral and topical treatments because they are instantly absorbed into the bloodstream.

Chemotherapy End-User Insights

 The chemotherapy market segmentation, based on end-user, includes specialty centers and hospitals & clinics. The hospitals & clinics segment, dominated the market throughout the projected period. The precise cancer treatment provided in hospitals, the presence of qualified medical personnel, the availability of cutting-edge medical equipment, and favorable reimbursement rules are all associated with the sub-segments rapid rise. In 2022, specialty centers saw the fastest growth rate. Specialist centers are expected to be created due to several causes, including the rise in chronic illness cases, the expansion of public-private partnerships in the healthcare sector, and the growing senior population.

Chemotherapy Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American chemotherapy market area will dominate this market. Multiple manufacturers of chemotherapy drugs and increased healthcare spending are North America's main market drivers. Accessibility to medical facilities and the application of cutting-edge technology in the study and treatment of cancer are other factors driving the market.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: CHEMOTHERAPY MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s chemotherapy market accounts for the second-largest market share. The main drivers influencing the market's growth are the ease of regulatory approval for novel cancer therapies in Europe, the rising incidence of cancer, and significant R&D spending by the major companies in the market. According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040. Further, the German chemotherapy market held the largest market share, and the UK chemotherapy market was the fastest-growing market in the European region

The Asia-Pacific Chemotherapy Market is estimated to expand at a rapid rate from 2024 to 2032. It results from expanded government awareness initiatives and rising healthcare costs in this area. Due to the availability of trained and qualified healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic medications will also help to slow the market's rate of progress in this sector. Moreover, China’s chemotherapy market held the largest market share, and the Indian chemotherapy market was the fastest-growing market in the Asia-Pacific region.

Chemotherapy Competitive Insights & Key Market Players

Leading market players are largely investing in R&D to expand their production capacities, which will aid in the further expansion of the chemotherapy industry. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The chemotherapy industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the chemotherapy industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. Recently, the chemotherapy industry has stipulated some of the most important medicinal benefits. Major players in the chemotherapy market, including Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US), and others, are funding operations for research and development to boost market demand.

Gland Pharma, founded in 1978 in Hyderabad, India, has evolved from a contract manufacturer [HK1] of small volume liquid parenteral products to one of the world's largest and fastest growing generic injectables manufacturing companies, with a footprint spanning 60 countries, including the Europe, United States, Canada, Australia, India, and other markets. In May 2022, Gland Pharma, in collaboration with a partner, released Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US market. It is bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals U.S.A., Inc.'s reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial.

AstraZeneca was created in 1999 by merging Astra of Sweden and Zeneca Group of the United Kingdom. The company sells branded medications in various therapeutic areas, including gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Most sales are done in foreign markets, with the United States making up nearly one-third of the total. In July 2021, AstraZeneca announced that the National Medical Products Administration (NMPA) had approved Imfinzi (durvalumab) for marketing in China for the medical management of patients with Stage III unresectable non-small cell lung cancer whose cancer did not advance following concurrent platinum-based chemotherapy and radiation therapy.

Key Companies in the chemotherapy market include

• Johnson & Johnson Services Inc (US)


• GlaxoSmithKline PLC (UK)


• Eli Lilly and Company (US)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• 
  Merck & Co. Inc. (US)


• Sanofi S.A. (France)


• Celgene Corporation (US)


• Bristol-Myers Squibb Company

Chemotherapy Industry Developments

August 2022:Ipsen announced the completion of the definitive merger agreement that would see Ipsen acquire Epizyme, Inc. (Epizyme). Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor awarded Accelerated Approval by US Food and Drug Administration in 2020, is acquired by Ipsen as part of the agreement.

September 2020:Gilead Sciences Inc announced a $21 billion acquisition of Immunomedics Inc, boosting its cancer portfolio by obtaining access to a promising medicine. The agreement grants Gilead access to Immunomedics' breast cancer treatment medicine Trodelvy, which received fast FDA approval in April for an aggressive and difficult-to-treat kind of breast cancer.

Chemotherapy Market Segmentation

Chemotherapy Drug Class Outlook

• 
  

  Mitotic Inhibitors

  
  


• 
  

  Alkylating Agents

  
  


• 
  

  Antimetabolites

  
  


• 
  

  Topoisomerase Inhibitors

  
  


• 
  

  Antitumor Antibiotic

  
  

Chemotherapy Indication Outlook

• 
  

  Breast Cancer

  
  


• 
  

  Lung Cancer

  
  


• 
  

  Colorectal Cancer

  
  


• 
  

  Prostate Cancer

  
  


• 
  

  Stomach Cancer

  
  


• 
  

  Lymphoma

  
  


• 
  

  Leukemia

  
  


• 
  

  Ovarian Cancer

  
  

Chemotherapy Route of Drug Administration Outlook

• 
  

  Intravenous

  
  


• 
  

  Oral

  
  


• 
  

  Subcutaneous

  
  


• 
  

  Intra-Muscular

  
  


• 
  

  Intravesicular

  
  


• 
  

  Topical

  
  


• 
  

  Intraperitoneal

  
  


• 
  

  Intraventricular/Intrathecal

  
  

Chemotherapy End-User Outlook

• 
  

  Specialty Centers

  
  


• 
  

  Hospitals & Clinics

  
  

Chemotherapy Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America